HemoCath is committed to improving healthcare for people living with heart failure.
HemoCath is committed to improving healthcare for people living with heart failure.
HemoCath Medical Ltd. is an Irish/US Digital Health & MedTech startup transforming heart failure (HF) care with the HemoCath™ Hemodynamic AI Platform — a first-of-its-kind, scalable solution for real-time diagnosis, treatment, and monitoring of HF patients.
The platform combines the HemoCath™ pulmonary artery catheter with the HemoDynamix™ AI Cloud (B2B AIoT/SaaS) to translate continuous, accurate cardiovascular hemodynamic data into clear actionable insights. Clinicians get faster, AI-guided decisions — improving patient outcomes, shortening hospital stays, and lowering healthcare costs.
Our leadership team has over 100 years of combined experience in medical devices, engineering, commercialization, and corporate finance, with a proven track record in product development, business strategy, and successfully bringing innovations to market.
Experienced entrepreneur and engineer with a strong background in medical devices, digital health, and high-tech industries. Demonstrated success in leading ventures from concept to commercialization and exit. With over 25 years of industry and leadership experience, Eric has held key roles across engineering R&D, product development, manufacturing, commercialization, finance, sales, and marketing. He holds a Bachelor’s degree in Engineering and an MBA.
Des Regan is an expert in engineering development of novel medical devices, with an impressive track record over the past 30 years. He founded and lead a number of startup companies developing medical devices in Ireland. Des has been Director of Product Development since 2003 with established companies such as Nordson Medical, Phillips Medisize and Medtronic. Inventor on 23 patents in the medical field. He holds a BS and MS in mechanical engineering.
Dr. Christopher Glover is Interventional Cardiologist and Director of Cardiac Catheterization at the University of Ottawa Heart Institute. Dr. Glover is also Associate Professor and Director of Education and Clinical Services in the division of cardiology at the University of Ottawa. With over 25 years of experience as an interventional cardiologist, he has developed extensive expertise in cardiac diseases and transcatheter valve replacements.
Seasoned corporate development strategist with 20 years of public practice with M&A at PwC and Deloitte. Chartered Professional Accountant, Chartered Business Valuators and senior member of American Society of Appraiser with a specialty in business valuation. Since 2010, co-founder & CEO of Life360 Innovations, commercializing a medical device for men with urinary incontinence. In addition, a board member and advisor for a number of companies.
At HemoCath, we are dedicated to advancing healthcare with the next generation of pulmonary artery catheters. Our mission is to enhance patient outcomes through innovative, precise, and reliable hemodynamic monitoring solutions. We strive to empower healthcare professionals with cutting-edge medical technology that improves decision-making, optimizes treatment, and sets new standards in cardiovascular care.